about
Primary Prevention Implantable Cardioverter Defibrillator (ICD) Therapy in Women-Data From a Multicenter French Registry.FAP neuropathy and emerging treatments.Interventricular differences in β-adrenergic responses in the canine heart: role of phosphodiesterases.Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in FranceThe value of basic research insights into atrial fibrillation mechanisms as a guide to therapeutic innovation: a critical analysisIndications of anti-inflammatory drugs in cardiac diseases.Targeted therapies in pulmonary arterial hypertension.Current and future treatment of amyloid neuropathies.Association Between Mutation Size and Cardiac Involvement in Myotonic Dystrophy Type 1: An Analysis of the DM1-Heart Registry.TTR kinetic stabilizers and TTR gene silencing: a new era in therapy for familial amyloidotic polyneuropathies.Potassium Channel Remodeling in Heart Disease.Very high rate programming in primary prevention patients with reduced ejection fraction implanted with a defibrillator: Results from a large multicenter controlled study.Outcome and incidence of appropriate implantable cardioverter-defibrillator therapy in patients with cardiac amyloidosis.Does defibrillation testing influence outcomes after CRT-D implantation? A cause-of-death analysis from the DAI-PP study.Impact of early complications on outcomes in patients with implantable cardioverter-defibrillator for primary prevention.Temporal Trends Over a Decade of Defibrillator Therapy for Primary Prevention in Community Practice.Outcome of Primary Prevention Implantable Cardioverter Defibrillator Therapy According to New York Heart Association Functional Classification.Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge.Contraction delay of the RV outflow tract in patients with Brugada syndrome is dependent on the spontaneous ST-segment elevation pattern.Electrocardiographic abnormalities in centenarians and octogenarians: a case-matched study.Comparison of MIBG and Diphosphonate scintigraphy in cardiac involvement of aTTR-FAP.[18F]FDDNP performed better than [18F] Florbetapir to distinguish transthyretin cardiac amyloidosis (TTR-CA) patients from healthy controls: an ex vivo study.Therapeutic education programme in TTR-FAP.Multi-modality imaging in cardiac ATTR amyloidosis: agreement between echocardiography, MRI and DPD-scintigraphy.Disphosphonates cardiac uptake in familial amyloid neuropathy: Comparison between DPD and HMDP.Protease-activated receptor-1 mediates thrombin-induced persistent sodium current in human cardiomyocytes.A Clinical and Echocardiographic Score to Identify Pulmonary Hypertension Due to HFpEF.Combination of the best pacing configuration and atrioventricular and interventricular delays optimization in cardiac resynchronization therapy.Multimodality Imaging of Cardiac Transthyretin Amyloidosis 16 years after a Domino Liver Transplantation.Spectrum and Outcome of Patients Who Have Undergone Implantation of an Implantable Cardioverter Defibrillator After Aborted-Sudden Cardiac Arrest.Familial amyloid polyneuropathy: elaboration of a therapeutic patient education programme, "EdAmyl".Dual- vs. single-chamber defibrillators for primary prevention of sudden cardiac death: long-term follow-up of the Défibrillateur Automatique Implantable-Prévention Primaire registry.Cardiac Dysautonomia Predicts Long-Term Survival in Hereditary Transthyretin Amyloidosis After Liver Transplantation.Effect of age on survival and causes of death after primary prevention implantable cardioverter-defibrillator implantation.Value of mechanical dyssynchrony as assessed by radionuclide ventriculography to predict the cardiac resynchronization therapy response.Cardiac denervation evidenced by MIBG occurs earlier than amyloid deposits detection by diphosphonate scintigraphy in TTR mutation carriers.Abnormal sodium current properties contribute to cardiac electrical and contractile dysfunction in a mouse model of myotonic dystrophy type 1.Prediction of long-term survival after liver transplantation for familial transthyretin amyloidosis.[Multidetector computed tomography coronarography: from studies to everyday life].Brugada syndrome and abnormal splicing of SCN5A in myotonic dystrophy type 1.
P50
Q31044974-932046A3-0B57-443C-BB58-1E4E4AA0B337Q34401190-8D4C294C-04FB-425D-8458-8B1C070A51D3Q35021924-6D3BF884-14BA-403F-B8B5-1435E1D74FDFQ36536822-BA46BA99-39CC-4ECA-A005-AEDF2F7E9EE2Q36650575-F7A42761-29E7-438C-B939-AE1B44D55D3EQ38071322-38880DD7-AF4B-4854-B71C-6FD549389277Q38153497-4C049233-D393-4E19-89C5-622D7F8D5C70Q38270497-8229C171-2F48-4181-9C1F-B084E5C82BE9Q38375648-989871C1-B8D9-43CE-988E-1214B466DEF0Q38708201-2D4B1AF7-BACF-4F97-AA03-41980E15272EQ38854260-95BB2CCA-98EB-4FBD-ADE7-155886216E21Q39090624-05B11250-264B-4D94-9876-878F2CAAEC09Q39499997-1DDCC387-054A-4A39-9B17-D462DFC850E8Q39577423-FA82468E-A47E-4337-A216-5B1781231084Q40125050-6E33E39D-F78B-4E6D-98DE-CDC021174164Q40311907-66029F18-4F82-4B2C-869B-F70E2A6D41AFQ40607450-9FBCAD43-D0B7-448C-AC65-F957CFF04636Q41064083-C07F0F83-0143-456C-8CAE-C44EE44179BAQ45149179-F958230F-0E43-4DCE-B90F-07D6DEA7FE8AQ45758291-BA99BEBD-8FCB-4062-8DE3-B52D205AE626Q45851242-E97C470E-B942-43F3-8937-8BB993D4525CQ45851589-7E7CA85D-DA15-47C2-8EE2-9A3518983DFFQ45851825-08648C19-37D0-4AC0-8154-0E0DF21142F3Q45851869-09838C62-02B0-47AE-8CB3-6F332677A9A4Q45851933-81F664A8-F7FF-49B8-9189-55E2AAA0700EQ46714279-AE72983C-A38C-4380-A901-8C0D7E43487DQ47806912-30B82B05-B3C5-4E9B-83A3-F9E49BF86D90Q48100016-031A7BE9-3AF4-47D2-9115-13B2B2D771DDQ48238191-7400A7E8-34D5-43D9-A602-44587E7B6360Q49886722-33AFD61C-014A-437C-84A1-14414EA5516EQ50630626-70BBE175-F4DE-450D-B2ED-CE558A0CBD9EQ50946930-AE7B26C6-8515-4748-9CF7-6C610F1B4656Q51067275-7A7A53B9-E20F-4EA5-9732-A6C8713098D9Q51275977-B68882F4-A95B-440C-BFB8-16DA64C5446BQ51627060-7A3D8440-9AAE-4C80-A87F-84ABB07EAD96Q52670660-838B8868-31F4-4205-86CE-CD4795754121Q52973356-359262B8-7C00-4FBD-8DC6-B3721938D4DAQ53293285-FE45903A-D759-4811-875D-7CA7D2ED2470Q53352147-CC472373-088A-4EB1-8070-2684E1AB907BQ54401968-72A79EE1-49B4-4E68-A861-B6696C29483B
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Vincent Algalarrondo
@ast
Vincent Algalarrondo
@en
Vincent Algalarrondo
@es
Vincent Algalarrondo
@nl
Vincent Algalarrondo
@sl
type
label
Vincent Algalarrondo
@ast
Vincent Algalarrondo
@en
Vincent Algalarrondo
@es
Vincent Algalarrondo
@nl
Vincent Algalarrondo
@sl
prefLabel
Vincent Algalarrondo
@ast
Vincent Algalarrondo
@en
Vincent Algalarrondo
@es
Vincent Algalarrondo
@nl
Vincent Algalarrondo
@sl
P106
P21
P31
P496
0000-0001-5971-1235